Inhibitors of cyclin-dependent kinases as cancer therapeutics

Pharmacology and Therapeutics

Volumn 173, Issue , 2017, Pages 83-105

  Whittaker, Steven R ^a   Mallinger, Aurélie ^a   Workman, Paul ^a   Clarke, Paul A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cell cycle; Cyclin dependent kinase; Inhibitor; Transcription

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; PALBOCICLIB; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

CANCER CELL; CELL CYCLE REGULATION; CELL PROLIFERATION; DRUG RESISTANCE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HEALTH CARE QUALITY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MALIGNANT NEOPLASM; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 85012892533     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.02.008     Document Type: Review

References (281)

1. Adler, A.S., McCleland, M.L., Truong, T., Lau, S., Modrusan, Z., Soukup, T.M.,.. Firestein, R., CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Research 72 (2012), 2129–2139.
2. Aklilu, M., Kindler, H.L., Donehower, R.C., Mani, S., Vokes, E.E., Phase II study of flavopiridol in patients with advanced colorectal cancer. Annals of Oncology 14 (2003), 1270–1273.
3. Aktas, H., Cai, H., Cooper, G.M., Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Molecular and Cellular Biology 17 (1997), 3850–3857.
4. Alarcon, C., Zaromytidou, A.I., Xi, Q., Gao, S., Yu, J., Fujisawa, S.,.. Massague, J., Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139 (2009), 757–769.
5. Albanese, C., Alzani, R., Amboldi, N., Avanzi, N., Ballinari, D., Brasca, M.G.,.. Ciomei, M., Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Molecular Cancer Therapeutics 9 (2010), 2243–2254.
6. Albert, T.K., Rigault, C., Eickhoff, J., Baumgart, K., Antrecht, C., Klebl, B.,.. Meisterernst, M., Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. British Journal of Pharmacology 171 (2014), 55–68.
7. Allen, B.L., Taatjes, D.J., The Mediator complex: A central integrator of transcription. Nature Reviews. Molecular Cell Biology 16 (2015), 155–166.
8. Amita Patnaik, L.S.R., Tolaney, S.M., Tolcher, A.W., Goldman, J.W., Gandhi, L., Papadopoulos, K.P.,.. Shapiro, G., LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR +) metastatic breast cancer. Journal of Clinical Oncology, 32, 2014 (abstr 534).
9. Anders, L., Ke, N., Hydbring, P., Choi, Y.J., Widlund, H.R., Chick, J.M.,.. Sicinski, P., A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20 (2011), 620–634.
10. Asghar, U., Witkiewicz, A.K., Turner, N.C., Knudsen, E.S., The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews. Drug Discovery 14 (2015), 130–146.
11. Bagella, L., Giacinti, C., Simone, C., Giordano, A., Identification of murine cdk10: Association with Ets2 transcription factor and effects on the cell cycle. Journal of Cellular Biochemistry 99 (2006), 978–985.
12. Bahleda, R., Gazzah, A., Varga, A., Rajagopalan, P., Henderson, D.A., Kornacker, M., Soria, J.-C., A first-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule. Journal of Clinical Oncology, 30, 2012.
13. Bajrami, I., Frankum, J.R., Konde, A., Miller, R.E., Rehman, F.L., Brough, R.,.. Ashworth, A., Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Research 74 (2014), 287–297.
14. Balmanno, K., Cook, S.J., Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18 (1999), 3085–3097.
15. Bancerek, J., Poss, Z.C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I.,.. Kovarik, P., CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 38 (2013), 250–262.
16. Barriere, C., Santamaria, D., Cerqueira, A., Galan, J., Martin, A., Ortega, S.,.. Barbacid, M., Mice thrive without Cdk4 and Cdk2. Molecular Oncology 1 (2007), 72–83.
17. Bartkowiak, B., Greenleaf, A.L., Phosphorylation of RNAPII: To P-TEFb or not to P-TEFb?. Transcription 2 (2011), 115–119.
18. Bartkowiak, B., Greenleaf, A.L., Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex. The Journal of Biological Chemistry 290 (2015), 1786–1795.
19. Bartkowiak, B., Liu, P., Phatnani, H.P., Fuda, N.J., Cooper, J.J., Price, D.H.,.. Greenleaf, A.L., CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes & Development 24 (2010), 2303–2316.
20. Bartkowiak, B., Yan, C., Greenleaf, A.L., Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas. Biochimica et Biophysica Acta 1849 (2015), 1179–1187.
21. Bataille, A.R., Jeronimo, C., Jacques, P.E., Laramee, L., Fortin, M.E., Forest, A.,.. Robert, F., A universal RNA polymerase II CTD cycle is orchestrated by complex interplays between kinase, phosphatase, and isomerase enzymes along genes. Molecular Cell 45 (2012), 158–170.
22. Baughn, L.B., Di Liberto, M., Wu, K., Toogood, P.L., Louie, T., Gottschalk, R.,.. Chen-Kiang, S., A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Research 66 (2006), 7661–7667.
23. Belenguer, P., Caizergues-Ferrer, M., Labbe, J.C., Doree, M., Amalric, F., Mitosis-specific phosphorylation of nucleolin by p34cdc2 protein kinase. Molecular and Cellular Biology 10 (1990), 3607–3618.
24. Benson, C., White, J., De Bono, J., O'Donnell, A., Raynaud, F., Cruickshank, C.,.. Twelves, C., A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. British Journal of Cancer 96 (2007), 29–37.
25. Bergeron, P., Koehler, M.F., Blackwood, E.M., Bowman, K., Clark, K., Firestein, R.,.. Beresini, M., Design and Development of a series of potent and selective type II inhibitors of CDK8. ACS Medicinal Chemistry Letters 7 (2016), 595–600.
26. Beyaert, R., Kidd, V.J., Cornelis, S., Van de Craen, M., Denecker, G., Lahti, J.M.,.. Fiers, W., Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor. The Journal of Biological Chemistry 272 (1997), 11694–11697.
27. Blais, A., Dynlacht, B.D., E2F-associated chromatin modifiers and cell cycle control. Current Opinion in Cell Biology 19 (2007), 658–662.
28. Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z.,.. Peterlin, B.M., The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes & Development 25 (2011), 2158–2172.
29. Bose, P., Simmons, G.L., Grant, S., Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opinion on Investigational Drugs 22 (2013), 723–738.
30. Bosken, C.A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D.,.. Geyer, M., The structure and substrate specificity of human Cdk12/Cyclin K. Nature Communications, 5, 2014, 3505.
31. Boss, D.S., Schwartz, G.K., Middleton, M.R., Amakye, D.D., Swaisland, H., Midgley, R.S.,.. Shapiro, G.I., Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumors. Annals of Oncology 21 (2010), 884–894.
32. Bragelmann, J., Klumper, N., Offermann, A., von Massenhausen, A., Bohm, D., Deng, M.,.. Perner, S., Pan-cancer analysis of the Mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer. Clinical Cancer Research, 2016 (Epub ahead of print).
33. Brandeis, M., Rosewell, I., Carrington, M., Crompton, T., Jacobs, M.A., Kirk, J.,.. Hunt, T., Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 4344–4349.
34. Brasca, M.G., Amboldi, N., Ballinari, D., Cameron, A., Casale, E., Cervi, G.,.. Ciomei, M., Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-py razolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. Journal of Medicinal Chemistry 52 (2009), 5152–5163.
35. Burdette-Radoux, S., Tozer, R.G., Lohmann, R.C., Quirt, I., Ernst, D.S., Walsh, W.,.. Eisenhauer, E.A., Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Investigational New Drugs 22 (2004), 315–322.
36. Byrd, J.C., Lin, T.S., Dalton, J.T., Wu, D., Phelps, M.A., Fischer, B.,.. Grever, M.R., Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007), 399–404.
37. Byrd, J.C., Peterson, B.L., Gabrilove, J., Odenike, O.M., Grever, M.R., Rai, K.,.. Cancer, & Leukemia Group, B, Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from Cancer and Leukemia Group B study 19805. Clinical Cancer Research 11 (2005), 4176–4181.
38. Byth, K.F., Thomas, A., Hughes, G., Forder, C., McGregor, A., Geh, C.,.. Wilkinson, R.W., AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Molecular Cancer Therapeutics 8 (2009), 1856–1866.
39. Carlson, B.A., Dubay, M.M., Sausville, E.A., Brizuela, L., Worland, P.J., Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Research 56 (1996), 2973–2978.
40. Carrera, I., Janody, F., Leeds, N., Duveau, F., Treisman, J.E., Pygopus activates wingless target gene transcription through the mediator complex subunits Med12 and Med13. Proceedings of the National Academy of Sciences of the United States of America 105 (2008), 6644–6649.
41. Cee, V.J., Chen, D.Y., Lee, M.R., Nicolaou, K.C., Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11. Angewandte Chemie (International Ed. in English) 48 (2009), 8952–8957.
42. Chattopadhyay, I., Singh, A., Phukan, R., Purkayastha, J., Kataki, A., Mahanta, J.,.. Kapur, S., Genome-wide analysis of chromosomal alterations in patients with esophageal squamous cell carcinoma exposed to tobacco and betel quid from high-risk area in India. Mutation Research 696 (2010), 130–138.
43. Chen, E.X., Hotte, S., Hirte, H., Siu, L.L., Lyons, J., Squires, M.,.. Seymour, L., A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. British Journal of Cancer 111 (2014), 2262–2267.
44. Chen, H.H., Wang, Y.C., Fann, M.J., Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Molecular and Cellular Biology 26 (2006), 2736–2745.
45. Chen, Z., Wang, Z., Pang, J.C., Yu, Y., Bieerkehazhi, S., Lu, J.,.. Yang, J., Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Scientific Reports, 6, 2016, 29090.
46. Chipumuro, E., Marco, E., Christensen, C.L., Kwiatkowski, N., Zhang, T., Hatheway, C.M.,.. George, R.E., CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159 (2014), 1126–1139.
47. Christensen, C.L., Kwiatkowski, N., Abraham, B.J., Carretero, J., Al-Shahrour, F., Zhang, T.,.. Wong, K.K., Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26 (2014), 909–922.
48. Clarke, P.A., Ortiz-Ruiz, M.-J., TePoele, R., Adeniji-Popoola, O., Box, G., Court, W.,.. Wienke, D., Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinase. eLife, 2016, 10.7554/eLife.20722.
49. Classon, M., Harlow, E., The retinoblastoma tumor suppressor in development and cancer. Nature Reviews. Cancer 2 (2002), 910–917.
50. Clevers, H., Nusse, R., Wnt/beta-catenin signaling and disease. Cell 149 (2012), 1192–1205.
51. Cocco, E., Lopez, S., Black, J., Bellone, S., Bonazzoli, E., Predolini, F.,.. Santin, A.D., Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal of Cancer 115 (2016), 303–311.
52. Corden, J.L., RNA polymerase II C-terminal domain: Tethering transcription to transcript and template. Chemical Reviews 113 (2013), 8423–8455.
53. Costa-Cabral, S., Brough, R., Konde, A., Aarts, M., Campbell, J., Marinari, E.,.. Ashworth, A., CDK1 Is a synthetic lethal target for KRAS mutant tumors. PLoS One, 11, 2016, e0149099.
54. Cristofanilli, M., Turner, N.C., Bondarenko, I., Ro, J., Im, S.A., Masuda, N.,.. Slamon, D., Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet Oncology 17 (2016), 425–439.
55. Czodrowski, P., Mallinger, A., Wienke, D., Esdar, C., Poeschke, O., Busch, M.,.. Schiemann, K., Structure-based optimization of potent, selective and orally bioavailable CDK8 inhibitors discovered by high throughput screening. Journal of Medicinal Chemistry 58 (2016), 9337–9349.
56. Dale, T., Clarke, P.A., Esdar, C., Waalboer, D., Adeniji-Popoola, O., Ortiz-Ruiz, M.J.,.. Blagg, J., A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature Chemical Biology 11 (2015), 973–980.
57. Davidson, L., Muniz, L., West, S., 3′ end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells. Genes & Development 28 (2014), 342–356.
58. Davidson, G., Shen, J., Huang, Y.L., Su, Y., Karaulanov, E., Bartscherer, K.,.. Niehrs, C., Cell cycle control of wnt receptor activation. Developmental Cell 17 (2009), 788–799.
59. Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G.,.. Zarrinkar, P.P., Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnology 29 (2011), 1046–1051.
60. Dean, J.L., Thangavel, C., McClendon, A.K., Reed, C.A., Knudsen, E.S., Therapeutic CDK4/6 inhibition in breast cancer: Key mechanisms of response and failure. Oncogene 29 (2010), 4018–4032.
61. Devaiah, B.N., Singer, D.S., Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation. The Journal of Biological Chemistry 287 (2012), 38755–38766.
62. Diab, S., Eckhardt, S., Tan, A., Frenette, G., Gore, L., Depinto, W.,.. Papadimitrakopoulou, S., A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs). Journal of Clinical Oncology, 25, 2007, 3528.
63. Dickson, M.A., Tap, W.D., Keohan, M.L., D'Angelo, S.P., Gounder, M.M., Antonescu, C.R.,.. Schwartz, G.K., Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of Clinical Oncology 31 (2013), 2024–2028.
64. Dolman, M.E., Poon, E., Ebus, M.E., den Hartog, I.J., van Noesel, C.J., Jamin, Y.,.. Molenaar, J.J., Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma. Clinical Cancer Research 21 (2015), 5100–5109.
65. Donner, A.J., Ebmeier, C.C., Taatjes, D.J., Espinosa, J.M., CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nature Structural & Molecular Biology 17 (2010), 194–201.
66. Drogat, J., Hermand, D., Gene-specific requirement of RNA polymerase II CTD phosphorylation. Molecular Microbiology 84 (2012), 995–1004.
67. Duan, Z., Zhang, J., Choy, E., Harmon, D., Liu, X., Nielsen, P.,.. Hornicek, F.J., Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clinical Cancer Research 18 (2012), 4580–4588.
68. Duarte, C.W., Willey, C.D., Zhi, D., Cui, X., Harris, J.J., Vaughan, L.K.,.. Gillespie, G.Y., Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One, 7, 2012, e29653.
69. Eick, D., Geyer, M., The RNA polymerase II carboxy-terminal domain (CTD) code. Chemical Reviews 113 (2013), 8456–8490.
70. Eifler, T.T., Shao, W., Bartholomeeusen, K., Fujinaga, K., Jager, S., Johnson, J.R.,.. Peterlin, B.M., Cyclin-dependent kinase 12 increases 3′ end processing of growth factor-induced c-FOS transcripts. Molecular and Cellular Biology 35 (2015), 468–478.
71. Feng, Y., Sassi, S., Shen, J.K., Yang, X., Gao, Y., Osaka, E.,.. Duan, Z., Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. Journal of Orthopaedic Research 33 (2015), 199–207.
72. Finn, R.S., Crown, J.P., Lang, I., Boer, K., Bondarenko, I.M., Kulyk, S.O.,.. Slamon, D.J., The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. The Lancet Oncology 16 (2015), 25–35.
73. Finn, R.S., Crown, J.P., Lang, I., Boer, K., Bondarenko, I.M., Kulyk, S.O.,.. Slamon, D.J., Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER +/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Cancer Research, 74, 2014, CT101.
74. Finn, R.S., Dering, J., Conklin, D., Kalous, O., Cohen, D.J., Desai, A.J.,.. Slamon, D.J., PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research, 11, 2009, R77.
75. Finn, R.S., Martin, M., Rugo, H.S., Jones, S.E., Im, S.-A., Gelmon, K.A.,.. Slamon, D.J., PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER +/HER2– advanced breast cancer (ABC). Journal of Clinical Oncology, 34, 2016 (abstr 507).
76. Firestein, R., Bass, A.J., Kim, S.Y., Dunn, I.F., Silver, S.J., Guney, I.,.. Hahn, W.C., CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455 (2008), 547–551.
77. Firestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E.,.. Ogino, S., CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. International Journal of Cancer 126 (2010), 2863–2873.
78. Fisher, R.P., The CDK network: Linking cycles of cell division and gene expression. Genes & Cancer 3 (2012), 731–738.
79. Flaherty, K.T., Lorusso, P.M., Demichele, A., Abramson, V.G., Courtney, R., Randolph, S.S.,.. Schwartz, G.K., Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clinical Cancer Research 18 (2012), 568–576.
80. Flynn, J., Jones, J., Johnson, A.J., Andritsos, L., Maddocks, K., Jaglowski, S.,.. Byrd, J.C., Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 29 (2015), 1524–1529.
81. Frame, S., Saladino, C., Davis, S., Blake, D., Zheleva, D., CYC065, potential therapeutic agent for AML and MLL leukaemia. SOHO Annual Meeting Proceedings, 2, 2014, 209.
82. Franck, N., Montembault, E., Rome, P., Pascal, A., Cremet, J.Y., Giet, R., CDK11(p58) is required for centriole duplication and Plk4 recruitment to mitotic centrosomes. PLoS One, 6, 2011, e14600.
83. Fribbens, C., O'Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M.,.. Turner, N.C., Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology 34 (2016), 2961–2968.
84. Fry, D.W., Harvey, P.J., Keller, P.R., Elliott, W.L., Meade, M., Trachet, E.,.. Toogood, P.L., Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics 3 (2004), 1427–1438.
85. Fryer, C.J., White, J.B., Jones, K.A., Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Molecular Cell 16 (2004), 509–520.
86. Furuno, N., den Elzen, N., Pines, J., Human cyclin A is required for mitosis until mid prophase. The Journal of Cell Biology 147 (1999), 295–306.
87. Galbraith, M.D., Allen, M.A., Bensard, C.L., Wang, X., Schwinn, M.K., Qin, B.,.. Espinosa, J.M., HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell 153 (2013), 1327–1339.
88. Ganuza, M., Saiz-Ladera, C., Canamero, M., Gomez, G., Schneider, R., Blasco, M.A.,.. Barbacid, M., Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. The EMBO Journal 31 (2012), 2498–2510.
89. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M.,.. Sellers, W.R., High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature Medicine 21 (2015), 1318–1325.
90. Garriga, J., Xie, H., Obradovic, Z., Grana, X., Selective control of gene expression by CDK9 in human cells. Journal of Cellular Physiology 222 (2010), 200–208.
91. Gelbert, L.M., Cai, S., Lin, X., Sanchez-Martinez, C., Del Prado, M., Lallena, M.J.,.. de Dios, A., Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investigational New Drugs 32 (2014), 825–837.
92. Ghia, P., Scarfo, L., Pathiraja, K., Derosier, M., Small, K., Patton, N., A phase 3 study to evaluate the efficacy and safety of dinaciclib compared to ofatumumab in patients with refractory chronic lymphocytic leukemia. Blood, 126, 2015, 4171.
93. Goh, K.C., Novotny-Diermayr, V., Hart, S., Ong, L.C., Loh, Y.K., Cheong, A.,.. Wood, J.M., TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 26 (2012), 236–243.
94. Gopinathan, L., Tan, S.L., Padmakumar, V.C., Coppola, V., Tessarollo, L., Kaldis, P., Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. Cancer Research 74 (2014), 3870–3879.
95. Gu, W., Wang, C., Li, W., Hsu, F.N., Tian, L., Zhou, J.,.. Ji, J.Y., Tumor-suppressive effects of CDK8 in endometrial cancer cells. Cell Cycle 12 (2013), 987–999.
96. Guen, V.J., Gamble, C., Flajolet, M., Unger, S., Thollet, A., Ferandin, Y.,.. Colas, P., CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), 19525–19530.
97. Gupta, K., Sari-Ak, D., Haffke, M., Trowitzsch, S., Berger, I., Zooming in on Transcription Preinitiation. Journal of Molecular Biology 428 (2016), 2581–2591.
98. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: The next generation. Cell 144 (2011), 646–674.
99. Harbeck, N., Iyer, S., Turner, N., Cristofanilli, M., Ro, J., Andre, F.,.. Loibl, S., Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: Patient-reported outcomes from the PALOMA-3 trial. Annals of Oncology 27 (2016), 1047–1054.
100. Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A., Dean, D.C., Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98 (1999), 859–869.
101. Heath, E.I., Bible, K., Martell, R.E., Adelman, D.C., Lorusso, P.M., A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Investigational New Drugs 26 (2008), 59–65.
102. Helin, K., Regulation of cell proliferation by the E2F transcription factors. Current Opinion in Genetics & Development 8 (1998), 28–35.
103. Herrera-Abreu, M.T., Palafox, M., Asghar, U., Rivas, M.A., Cutts, R.J., Garcia-Murillas, I.,.. Serra, V., Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Research 76 (2016), 2301–2313.
104. Hossain, D.M.S., Ugarte, F., Sawant, A., Cai, M., Sriram, V., Pinheiro, E.,.. Chackerian, A., Abstract 562: Dinaciclib induces immunogenic cell death and enhances anti-PD-1 mediated tumor suppression. Cancer Research, 76, 2016, 562.
105. Hu, D., Mayeda, A., Trembley, J.H., Lahti, J.M., Kidd, V.J., CDK11 complexes promote pre-mRNA splicing. The Journal of Biological Chemistry 278 (2003), 8623–8629.
106. Huang, J., Deng, Q., Wang, Q., Li, K.Y., Dai, J.H., Li, N.,.. Han, Z.G., Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nature Genetics 44 (2012), 1117–1121.
107. Huang, C.H., Lujambio, A., Zuber, J., Tschaharganeh, D.F., Doran, M.G., Evans, M.J.,.. Lowe, S.W., CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development 28 (2014), 1800–1814.
108. Infante, J.R., Cassier, P.A., Gerecitano, J.F., Witteveen, P.O., Chugh, R., Ribrag, V.,.. Shapiro, G.I., A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clinical Cancer Research 22 (2016), 5696–5705.
109. Iorns, E., Martens-de Kemp, S.R., Lord, C.J., Ashworth, A., CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Carcinogenesis 30 (2009), 1696–1701.
110. Iorns, E., Turner, N.C., Elliott, R., Syed, N., Garrone, O., Gasco, M.,.. Ashworth, A., Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13 (2008), 91–104.
111. Jasnovidova, O., Stefl, R., The CTD code of RNA polymerase II: A structural view. Wiley Interdisciplinary Reviews: RNA 4 (2013), 1–16.
112. Jeffrey, P.D., Russo, A.A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., Pavletich, N.P., Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376 (1995), 313–320.
113. Jeronimo, C., Bataille, A.R., Robert, F., The writers, readers, and functions of the RNA polymerase II C-terminal domain code. Chemical Reviews 113 (2013), 8491–8522.
114. Jeronimo, C., Collin, P., Robert, F., The RNA polymerase II CTD: The increasing complexity of a low-complexity protein domain. Journal of Molecular Biology 428 (2016), 2607–2622.
115. Jia, B., Choy, E., Cote, G., Harmon, D., Ye, S., Kan, Q.,.. Duan, Z., Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. Cancer Letters 342 (2014), 104–112.
116. Johnson, N., Cai, D., Kennedy, R.D., Pathania, S., Arora, M., Li, Y.C.,.. Shapiro, G.I., Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Molecular Cell 35 (2009), 327–339.
117. Johnson, N., Li, Y.C., Walton, Z.E., Cheng, K.A., Li, D., Rodig, S.J.,.. Shapiro, G.I., Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Medicine 17 (2011), 875–882.
118. Joshi, K.S., Rathos, M.J., Joshi, R.D., Sivakumar, M., Mascarenhas, M., Kamble, S.,.. Sharma, S., In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Molecular Cancer Therapeutics 6 (2007), 918–925.
119. Joshi, P.M., Sutor, S.L., Huntoon, C.J., Karnitz, L.M., Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. The Journal of Biological Chemistry 289 (2014), 9247–9253.
120. Juan, H.C., Lin, Y., Chen, H.R., Fann, M.J., Cdk12 is essential for embryonic development and the maintenance of genomic stability. Cell Death and Differentiation 23 (2016), 1038–1048.
121. Kalinichenko, V.V., Major, M.L., Wang, X., Petrovic, V., Kuechle, J., Yoder, H.M.,.. Costa, R.H., Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes & Development 18 (2004), 830–850.
122. Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T.,.. Zarrinkar, P.P., A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology 26 (2008), 127–132.
123. Kasten, M., Giordano, A., Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 20 (2001), 1832–1838.
124. Kauraniemi, P., Barlund, M., Monni, O., Kallioniemi, A., New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Research 61 (2001), 8235–8240.
125. Kauraniemi, P., Kuukasjarvi, T., Sauter, G., Kallioniemi, A., Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. The American Journal of Pathology 163 (2003), 1979–1984.
126. Kelso, T.W., Baumgart, K., Eickhoff, J., Albert, T., Antrecht, C., Lemcke, S.,.. Meisterernst, M., Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Molecular and Cellular Biology 34 (2014), 3675–3688.
127. Khodarev, N.N., Beckett, M., Labay, E., Darga, T., Roizman, B., Weichselbaum, R.R., STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proceedings of the National Academy of Sciences of the United States of America 101 (2004), 1714–1719.
128. Khodarev, N.N., Roizman, B., Weichselbaum, R.R., Molecular pathways: Interferon/stat1 pathway: Role in the tumor resistance to genotoxic stress and aggressive growth. Clinical Cancer Research 18 (2012), 3015–3021.
129. Kim, M.Y., Han, S.I., Lim, S.C., Roles of cyclin-dependent kinase 8 and beta-catenin in the oncogenesis and progression of gastric adenocarcinoma. International Journal of Oncology 38 (2011), 1375–1383.
130. Kim, S., Xu, X., Hecht, A., Boyer, T.G., Mediator is a transducer of Wnt/beta-catenin signaling. The Journal of Biological Chemistry 281 (2006), 14066–14075.
131. Knuesel, M.T., Meyer, K.D., Donner, A.J., Espinosa, J.M., Taatjes, D.J., The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Molecular and Cellular Biology 29 (2009), 650–661.
132. Ko, T.K., Kelly, E., Pines, J., CrkRS: A novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. Journal of Cell Science 114 (2001), 2591–2603.
133. Koehler, M.F., Bergeron, P., Blackwood, E.M., Bowman, K., Clark, K.R., Firestein, R.,.. Beresini, M.H., Development of a potent, specific CDK8 kinase inhibitor which phenocopies CDK8/19 knockout cells. ACS Medicinal Chemistry Letters 7 (2016), 223–228.
134. Kozar, K., Ciemerych, M.A., Rebel, V.I., Shigematsu, H., Zagozdzon, A., Sicinska, E.,.. Sicinski, P., Mouse development and cell proliferation in the absence of D-cyclins. Cell 118 (2004), 477–491.
135. Kren, B.T., Unger, G.M., Abedin, M.J., Vogel, R.I., Henzler, C.M., Ahmed, K., Trembley, J.H., Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. Breast Cancer Research, 17, 2015, 19.
136. Kumar, S.K., LaPlant, B., Chng, W.J., Zonder, J., Callander, N., Fonseca, R.,.. Stewart, A.K., Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125 (2015), 443–448.
137. Kwiatkowski, N., Zhang, T., Rahl, P.B., Abraham, B.J., Reddy, J., Ficarro, S.B.,.. Gray, N.S., Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511 (2014), 616–620.
138. Kwong, L.N., Costello, J.C., Liu, H., Jiang, S., Helms, T.L., Langsdorf, A.E.,.. Chin, L., Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nature Medicine 18 (2012), 1503–1510.
139. Lam, F., Abbas, A.Y., Shao, H., Teo, T., Adams, J., Li, P.,.. Wang, S., Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget 5 (2014), 7691–7704.
140. Lam, L.T., Pickeral, O.K., Peng, A.C., Rosenwald, A., Hurt, E.M., Giltnane, J.M.,.. Staudt, L.M., Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biology, 2, 2001 (RESEARCH0041).
141. Laoukili, J., Alvarez, M., Meijer, L.A., Stahl, M., Mohammed, S., Kleij, L.,.. Medema, R.H., Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. Molecular and Cellular Biology 28 (2008), 3076–3087.
142. Larochelle, S., Amat, R., Glover-Cutter, K., Sanso, M., Zhang, C., Allen, J.J.,.. Fisher, R.P., Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nature Structural & Molecular Biology 19 (2012), 1108–1115.
143. Lavoie, J.N., L'Allemain, G., Brunet, A., Muller, R., Pouyssegur, J., Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. The Journal of Biological Chemistry 271 (1996), 20608–20616.
144. Le Tourneau, C., Faivre, S., Laurence, V., Delbaldo, C., Vera, K., Girre, V.,.. Raymond, E., Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. European Journal of Cancer 46 (2010), 3243–3250.
145. Lee, M.S., Helms, T.L., Feng, N., Gay, J., Chang, Q.E., Tian, F.,.. Kopetz, S., Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget 7 (2016), 39595–39608.
146. Leung, W.K., Ching, A.K., Chan, A.W., Poon, T.C., Mian, H., Wong, A.S.,.. Wong, N., A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 30 (2011), 4464–4475.
147. Li, B., Carey, M., Workman, J.L., The role of chromatin during transcription. Cell 128 (2007), 707–719.
148. Liang, K., Gao, X., Gilmore, J.M., Florens, L., Washburn, M.P., Smith, E., Shilatifard, A., Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Molecular and Cellular Biology 35 (2015), 928–938.
149. Liu, M., Dai, B., Kang, S.H., Ban, K., Huang, F.J., Lang, F.F.,.. Huang, S., FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Research 66 (2006), 3593–3602.
150. Liu, G., Gandara, D.R., Lara, P.N. Jr., Raghavan, D., Doroshow, J.H., Twardowski, P.,.. Wilding, G., A phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clinical Cancer Research 10 (2004), 924–928.
151. Liu, Y., Ranish, J.A., Aebersold, R., Hahn, S., Yeast nuclear extract contains two major forms of RNA polymerase II mediator complexes. The Journal of Biological Chemistry 276 (2001), 7169–7175.
152. Liu, X., Shi, S., Lam, F., Pepper, C., Fischer, P.M., Wang, S., CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. International Journal of Cancer 130 (2012), 1216–1226.
153. Loyer, P., Trembley, J.H., Grenet, J.A., Busson, A., Corlu, A., Zhao, W.,.. Lahti, J.M., Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: Influence of cyclin L isoforms on splice site selection. The Journal of Biological Chemistry 283 (2008), 7721–7732.
154. Loyer, P., Trembley, J.H., Lahti, J.M., Kidd, V.J., The RNP protein, RNPS1, associates with specific isoforms of the p34cdc2-related PITSLRE protein kinase in vivo. Journal of Cell Science 111:Pt 11 (1998), 1495–1506.
155. MacCallum, D.E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A.,.. Green, S.R., Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Research 65 (2005), 5399–5407.
156. Mahadevan, D., Plummer, R., Squires, M.S., Rensvold, D., Kurtin, S., Pretzinger, C.,.. Calvert, H., A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Annals of Oncology 22 (2011), 2137–2143.
157. Mallinger, A., Crumpler, S., Pichowicz, M., Waalboer, D., Stubbs, M., Adeniji-Popoola, O.,.. Blagg, J., Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. Journal of Medicinal Chemistry 58 (2015), 1717–1735.
158. Mallinger, A., Schiemann, K., Rink, C., Stieber, F., Calderini, M., Crumpler, S.,.. Blagg, J., Discovery of potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. Journal of Medicinal Chemistry 59 (2016), 1078–1101.
159. Mallinger, A., Schiemann, K., Rink, C., Sejberg, J., Honey, M.A., Czodrowski, P.,.. Blagg, J., 2,8-Disubstituted-1,6-naphthyridines and 4,6-disubstituted-2-isoquinolines with potent, selective affinity for CDK8 and CDK19. ACS Medicinal Chemistry Letters 7 (2016), 573–578.
160. Malumbres, M., Cyclin-dependent kinases. Genome Biology, 15, 2014, 122.
161. Malumbres, M., Barbacid, M., Cell cycle, CDKs and cancer: A changing paradigm. Nature Reviews. Cancer 9 (2009), 153–166.
162. Malumbres, M., Harlow, E., Hunt, T., Hunter, T., Lahti, J.M., Manning, G.,.. Wolgemuth, D.J., Cyclin-dependent kinases: A family portrait. Nature Cell Biology 11 (2009), 1275–1276.
163. Malumbres, M., Sotillo, R., Santamaria, D., Galan, J., Cerezo, A., Ortega, S.,.. Barbacid, M., Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118 (2004), 493–504.
164. Marais, A., Ji, Z., Child, E.S., Krause, E., Mann, D.J., Sharrocks, A.D., Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK.cyclin complexes. The Journal of Biological Chemistry 285 (2010), 35728–35739.
165. Marshall, C., How do small GTPase signal transduction pathways regulate cell cycle entry?. Current Opinion in Cell Biology 11 (1999), 732–736.
166. Marzec, M., Kasprzycka, M., Lai, R., Gladden, A.B., Wlodarski, P., Tomczak, E.,.. Wasik, M.A., Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 108 (2006), 1744–1750.
167. Mayer, A., Lidschreiber, M., Siebert, M., Leike, K., Soding, J., Cramer, P., Uniform transitions of the general RNA polymerase II transcription complex. Nature Structural & Molecular Biology 17 (2010), 1272–1278.
168. McCleland, M.L., Soukup, T.M., Liu, S.D., Esensten, J.H., de Sousa e Melo, F., Yaylaoglu, M.,.. Firestein, R., Cdk8 deletion in the Apc(Min) murine tumor model represses EZH2 activity and accelerates tumorigenesis. The Journal of Pathology 237 (2015), 508–519.
169. Meijer, L., Borgne, A., Mulner, O., Chong, J.P., Blow, J.J., Inagaki, N.,.. Moulinoux, J.P., Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European Journal of Biochemistry 243 (1997), 527–536.
170. Merrick, K.A., Wohlbold, L., Zhang, C., Allen, J.J., Horiuchi, D., Huskey, N.E.,.. Fisher, R.P., Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Molecular Cell 42 (2011), 624–636.
171. Meyer, K.D., Donner, A.J., Knuesel, M.T., York, A.G., Espinosa, J.M., Taatjes, D.J., Cooperative activity of cdk8 and GCN5L within Mediator directs tandem phosphoacetylation of histone H3. The EMBO Journal 27 (2008), 1447–1457.
172. Mikolajczyk, M., Shi, J., Vaillancourt, R.R., Sachs, N.A., Nelson, M., The cyclin-dependent kinase 11(p46) isoform interacts with RanBPM. Biochemical and Biophysical Research Communications 310 (2003), 14–18.
173. Mita, M.M., Joy, A.A., Mita, A., Sankhala, K., Jou, Y.M., Zhang, D.,.. Shapiro, C.L., Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clinical Breast Cancer 14 (2014), 169–176.
174. Mitra, A.P., Almal, A.A., George, B., Fry, D.W., Lenehan, P.F., Pagliarulo, V.,.. Worzel, W.P., The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer, 6, 2006, 159.
175. Mittnacht, S., Lees, J.A., Desai, D., Harlow, E., Morgan, D.O., Weinberg, R.A., Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. The EMBO Journal 13 (1994), 118–127.
176. Morris, E.J., Ji, J.Y., Yang, F., Di Stefano, L., Herr, A., Moon, N.S.,.. Dyson, N.J., E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455 (2008), 552–556.
177. Mueller, P.R., Coleman, T.R., Kumagai, A., Dunphy, W.G., Myt1: A membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270 (1995), 86–90.
178. Murphy, M., Stinnakre, M.G., Senamaud-Beaufort, C., Winston, N.J., Sweeney, C., Kubelka, M.,.. Sobczak-Thepot, J., Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nature Genetics 15 (1997), 83–86.
179. Narasimha, A.M., Kaulich, M., Shapiro, G.S., Choi, Y.J., Sicinski, P., Dowdy, S.F., Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. eLife, 3, 2014, e02872.
180. Nemeth, G., Greff, Z., Sipos, A., Varga, Z., Szekely, R., Sebestyen, M.,.. Orfi, L., Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors. Journal of Medicinal Chemistry 57 (2014), 3939–3965.
181. Nemunaitis, J.J., Small, K.A., Kirschmeier, P., Zhang, D., Zhu, Y., Jou, Y.M.,.. Bannerji, R., A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. Journal of Translational Medicine, 11, 2013, 259.
182. Nilson, K.A., Guo, J., Turek, M.E., Brogie, J.E., Delaney, E., Luse, D.S., Price, D.H., THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing. Molecular Cell 59 (2015), 576–587.
183. Nurse, P., A long twentieth century of the cell cycle and beyond. Cell 100 (2000), 71–78.
184. Ortega, S., Prieto, I., Odajima, J., Martin, A., Dubus, P., Sotillo, R.,.. Barbacid, M., Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nature Genetics 35 (2003), 25–31.
185. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., Draetta, G., Cyclin A is required at two points in the human cell cycle. The EMBO Journal 11 (1992), 961–971.
186. Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D.,.. Lees, E.M., Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Molecular Cancer Therapeutics 9 (2010), 2344–2353.
187. Patel, H., Abduljabbar, R., Lai, C.F., Periyasamy, M., Harrod, A., Gemma, C.,.. Ali, S., CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer. Clinical Cancer Research 22 (2016), 5929–5938.
188. Patnaik, A., Rosen, L.S., Tolaney, S.M., Tolcher, A.W., Goldman, J.W., Gandhi, L.,.. Shapiro, G.I., Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discovery 6 (2016), 740–753.
189. Peeper, D.S., Upton, T.M., Ladha, M.H., Neuman, E., Zalvide, J., Bernards, R.,.. Ewen, M.E., Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386 (1997), 177–181.
190. Pelish, H.E., Liau, B.B., Nitulescu, I.I., Tangpeerachaikul, A., Poss, Z.C., Da Silva, D.H.,.. Shair, M.D., Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 526 (2015), 273–276.
191. Peter, M., Nakagawa, J., Doree, M., Labbe, J.C., Nigg, E.A., Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase. Cell 60 (1990), 791–801.
192. Peter, M., Nakagawa, J., Doree, M., Labbe, J.C., Nigg, E.A., In vitro disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by cdc2 kinase. Cell 61 (1990), 591–602.
193. Petretti, C., Savoian, M., Montembault, E., Glover, D.M., Prigent, C., Giet, R., The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Reports 7 (2006), 418–424.
194. Polier, G., Ding, J., Konkimalla, B.V., Eick, D., Ribeiro, N., Kohler, R.,.. Li-Weber, M., Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death & Disease, 2, 2011, e182.
195. Poon, E., Jamin, Y., Walz, S., Hakkert, S., Kwok, C., Hallsworth, A.,.. Chesler, L., The small molecule CDK2 and CDK9 inhibitors CYC065 and CCT68127 are potent inhibitors of MYCN via transcriptional repression. Childhood Cancer Meeting 2016, September 5 – 7, London, UK, 2016 (Abs. 1-19).
196. Porter, D.C., Farmaki, E., Altilia, S., Schools, G.P., West, D.K., Chen, M.,.. Roninson, I.B., Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 13799–13804.
197. Poss, Z.C., Ebmeier, C.C., Taatjes, D.J., The Mediator complex and transcription regulation. Critical Reviews in Biochemistry and Molecular Biology 48 (2013), 575–608.
198. Pozo, K., Castro-Rivera, E., Tan, C., Plattner, F., Schwach, G., Siegl, V.,.. Bibb, J.A., The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell 24 (2013), 499–511.
199. Putz, E.M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A.,.. Sexl, V., CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Reports 4 (2013), 437–444.
200. Puyol, M., Martin, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G.,.. Barbacid, M., A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18 (2010), 63–73.
201. Rader, J., Russell, M.R., Hart, L.S., Nakazawa, M.S., Belcastro, L.T., Martinez, D.,.. Maris, J.M., Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clinical Cancer Research 19 (2013), 6173–6182.
202. Rae, J.M., Creighton, C.J., Meck, J.M., Haddad, B.R., Johnson, M.D., MDA-MB-435 cells are derived from M14 melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Research and Treatment 104 (2007), 13–19.
203. Rakkaa, T., Escude, C., Giet, R., Magnaghi-Jaulin, L., Jaulin, C., CDK11(p58) kinase activity is required to protect sister chromatid cohesion at centromeres in mitosis. Chromosome Research 22 (2014), 267–276.
204. Ramakrishnan, R., Rice, A.P., Cdk9 T-loop phosphorylation is regulated by the calcium signaling pathway. Journal of Cellular Physiology 227 (2012), 609–617.
205. Rane, S.G., Dubus, P., Mettus, R.V., Galbreath, E.J., Boden, G., Reddy, E.P., Barbacid, M., Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nature Genetics 22 (1999), 44–52.
206. Raynaud, F.I., Whittaker, S.R., Fischer, P.M., McClue, S., Walton, M.I., Barrie, S.E.,.. Workman, P., In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clinical Cancer Research 11 (2005), 4875–4887.
207. Rocha, P.P., Scholze, M., Bleiss, W., Schrewe, H., Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. Development 137 (2010), 2723–2731.
208. Rodgers, J.T., King, K.Y., Brett, J.O., Cromie, M.J., Charville, G.W., Maguire, K.K.,.. Rando, T.A., mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature 510 (2014), 393–396.
209. Rossi, D.J., Londesborough, A., Korsisaari, N., Pihlak, A., Lehtonen, E., Henkemeyer, M., Makela, T.P., Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1. The EMBO Journal 20 (2001), 2844–2856.
210. Russo, A.A., Jeffrey, P.D., Pavletich, N.P., Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Structural Biology 3 (1996), 696–700.
211. Rzymski, T., Mikula, M., Wiklik, K., Brzozka, K., CDK8 kinase–An emerging target in targeted cancer therapy. Biochimica et Biophysica Acta 1854 (2015), 1617–1629.
212. Sadasivam, S., Duan, S., DeCaprio, J.A., The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes & Development 26 (2012), 474–489.
213. Sanchez-Martinez, C., Gelbert, L.M., Lallena, M.J., de Dios, A., Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorganic & Medicinal Chemistry Letters 25 (2015), 3420–3435.
214. Santamaria, D., Barriere, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K.,.. Barbacid, M., Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448 (2007), 811–815.
215. Scaltriti, M., Eichhorn, P.J., Cortes, J., Prudkin, L., Aura, C., Jimenez, J.,.. Baselga, J., Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America 108 (2011), 3761–3766.
216. Schiemann, K., Mallinger, A., Wienke, D., Esdar, C., Poeschke, O., Busch, M.,.. Blagg, J., Discovery of Potent and Selective CDK8 Inhibitors from an HSP90 Pharmacophore. Bioorganic and Medicinal Chemistry Letters 26 (2016), 1443–1451.
217. Schneider, E.V., Bottcher, J., Blaesse, M., Neumann, L., Huber, R., Maskos, K., The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. Journal of Molecular Biology 412 (2011), 251–266.
218. Schwartz, G.K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P.,.. Kelsen, D., Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. Journal of Clinical Oncology 19 (2001), 1985–1992.
219. Schwartz, G.K., LoRusso, P.M., Dickson, M.A., Randolph, S.S., Shaik, M.N., Wilner, K.D.,.. O'Dwyer, P.J., Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). British Journal of Cancer 104 (2011), 1862–1868.
220. Seo, J.O., Han, S.I., Lim, S.C., Role of CDK8 and beta-catenin in colorectal adenocarcinoma. Oncology Reports 24 (2010), 285–291.
221. Shao, H., Shi, S., Huang, S., Hole, A.J., Abbas, A.Y., Baumli, S.,.. Wang, S., Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. Journal of Medicinal Chemistry 56 (2013), 640–659.
222. Sherr, C.J., Cancer cell cycles. Science 274 (1996), 1672–1677.
223. Sherr, C.J., Roberts, J.M., CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes & Development 13 (1999), 1501–1512.
224. Shi, J., Feng, Y., Goulet, A.C., Vaillancourt, R.R., Sachs, N.A., Hershey, J.W., Nelson, M.A., The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. The Journal of Biological Chemistry 278 (2003), 5062–5071.
225. Shiraishi, Y., Fujimoto, A., Furuta, M., Tanaka, H., Chiba, K., Boroevich, K.A.,.. Nakagawa, H., Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers. PLoS One, 9, 2014, e114263.
226. Siemeister, G., Lucking, U., Wengner, A.M., Lienau, P., Steinke, W., Schatz, C.,.. Ziegelbauer, K., BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Molecular Cancer Therapeutics 11 (2012), 2265–2273.
227. Sonawane, Y.A., Taylor, M.A., Napoleon, J.V., Rana, S., Contreras, J.I., Natarajan, A., Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry 59 (2016), 8667–8684.
228. Squires, M.S., Cooke, L., Lock, V., Qi, W., Lewis, E.J., Thompson, N.T.,.. Mahadevan, D., AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Molecular Cancer Therapeutics 9 (2010), 920–928.
229. Squires, M.S., Feltell, R.E., Wallis, N.G., Lewis, E.J., Smith, D.M., Cross, D.M.,.. Thompson, N.T., Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Molecular Cancer Therapeutics 8 (2009), 324–332.
230. Storch, K., Cordes, N., The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells. International Journal of Oncology 48 (2016), 191–198.
231. Strelkov, I.S., Davie, J.R., Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. Cancer Research 62 (2002), 75–78.
232. Sun, T., Co, N.N., Wong, N., PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 449 (2014), 163–168.
233. Taatjes, D.J., Naar, A.M., Andel, F. 3rd, Nogales, E., Tjian, R., Structure, function, and activator-induced conformations of the CRSP coactivator. Science 295 (2002), 1058–1062.
234. Takahashi, H., Parmely, T.J., Sato, S., Tomomori-Sato, C., Banks, C.A., Kong, S.E.,.. Conaway, J.W., Human mediator subunit MED26 functions as a docking site for transcription elongation factors. Cell 146 (2011), 92–104.
235. Tetsu, O., McCormick, F., Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3 (2003), 233–245.
236. Tiedemann, R.E., Zhu, Y.X., Schmidt, J., Shi, C.X., Sereduk, C., Yin, H.,.. Stewart, A.K., Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Research 72 (2012), 757–768.
237. Tiedemann, R.E., Zhu, Y.X., Schmidt, J., Yin, H., Shi, C.X., Que, Q.,.. Stewart, A.K., Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 115 (2010), 1594–1604.
238. Tolaney, S.M., Hilton, J.F., Cleary, J.M., Gandhi, L., Kwak, E.L., Clark, J.W.,.. Shapiro, G., Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors. Journal of Clinical Oncology, 34, 2016 (abstr 2503).
239. Tong, W.G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R.D.,.. Wierda, W.G., Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Journal of Clinical Oncology 28 (2010), 3015–3022.
240. Treiber, D.K., Shah, N.P., Ins and outs of kinase DFG motifs. Chemistry & Biology 20 (2013), 745–746.
241. Trembley, J.H., Hu, D., Hsu, L.C., Yeung, C.Y., Slaughter, C., Lahti, J.M., Kidd, V.J., PITSLRE p110 protein kinases associate with transcription complexes and affect their activity. The Journal of Biological Chemistry 277 (2002), 2589–2596.
242. Trembley, J.H., Loyer, P., Hu, D., Li, T., Grenet, J., Lahti, J.M., Kidd, V.J., Cyclin dependent kinase 11 in RNA transcription and splicing. Progress in Nucleic Acid Research and Molecular Biology 77 (2004), 263–288.
243. Tsai, K.L., Sato, S., Tomomori-Sato, C., Conaway, R.C., Conaway, J.W., Asturias, F.J., A conserved Mediator-CDK8 kinase module association regulates Mediator-RNA polymerase II interaction. Nature Structural & Molecular Biology 20 (2013), 611–619.
244. Tsutsui, T., Hesabi, B., Moons, D.S., Pandolfi, P.P., Hansel, K.S., Koff, A., Kiyokawa, H., Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Molecular and Cellular Biology 19 (1999), 7011–7019.
245. Tsutsui, T., Umemura, H., Tanaka, A., Mizuki, F., Hirose, Y., Ohkuma, Y., Human mediator kinase subunit CDK11 plays a negative role in viral activator VP16-dependent transcriptional regulation. Genes to Cells 13 (2008), 817–826.
246. Turner, N.C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H.,.. Cristofanilli, M., Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine 373 (2015), 209–219.
247. van den Heuvel, S., Harlow, E., Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262 (1993), 2050–2054.
248. Verma, S., Bartlett, C.H., Schnell, P., DeMichele, A.M., Loi, S., Ro, J.,.. Rugo, H.S., Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: Detailed safety analysis from a multicenter, randomized, placebo-controlled, Phase III Study (PALOMA-3). The Oncologist 21 (2016), 1165–1175.
249. Viladevall, L., St Amour, C.V., Rosebrock, A., Schneider, S., Zhang, C., Allen, J.J.,.. Fisher, R.P., TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Molecular Cell 33 (2009), 738–751.
250. Vora, S.R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C.,.. Engelman, J.A., CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26 (2014), 136–149.
251. Walsby, E., Pratt, G., Shao, H., Abbas, A.Y., Fischer, P.M., Bradshaw, T.D.,.. Pepper, C., A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget 5 (2014), 375–385.
252. Wang, S., Fischer, P.M., Cyclin-dependent kinase 9: A key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends in Pharmacological Sciences 29 (2008), 302–313.
253. Wang, I.C., Chen, Y.J., Hughes, D.E., Ackerson, T., Major, M.L., Kalinichenko, V.V.,.. Lau, L.F., FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. The Journal of Biological Chemistry 283 (2008), 20770–20778.
254. Wang, I.C., Chen, Y.J., Hughes, D., Petrovic, V., Major, M.L., Park, H.J.,.. Costa, R.H., Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Molecular and Cellular Biology 25 (2005), 10875–10894.
255. Wang, S., Griffiths, G., Midgley, C.A., Barnett, A.L., Cooper, M., Grabarek, J.,.. Fischer, P.M., Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chemistry & Biology 17 (2010), 1111–1121.
256. Wang, Z.Q., Johnson, C.L., Kumar, A., Molkentine, D.P., Molkentine, J.M., Rabin, T.,.. Raju, U., Inhibition of P-TEFb by DRB suppresses SIRT1/CK2alpha pathway and enhances radiosensitivity of human cancer cells. Anticancer Research 34 (2014), 6981–6989.
257. Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B.J., Lee, T.I., Xie, S.,.. Zhao, J.J., CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163 (2015), 174–186.
258. Weiss, G.J., Hidalgo, M., Borad, M.J., Laheru, D., Tibes, R., Ramanathan, R.K.,.. Von Hoff, D.D., Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Investigational New Drugs 30 (2012), 2334–2343.
259. Westerling, T., Kuuluvainen, E., Makela, T.P., Cdk8 is essential for preimplantation mouse development. Molecular and Cellular Biology 27 (2007), 6177–6182.
260. Whittaker, S.R., Te Poele, R.H., Chan, F., Linardopoulos, S., Walton, M.I., Garrett, M.D., Workman, P., The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 6 (2007), 3114–3131.
261. Whittaker, S.R., Walton, M.I., Garrett, M.D., Workman, P., The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Research 64 (2004), 262–272.
262. William, A.D., Lee, A.C., Goh, K.C., Blanchard, S., Poulsen, A., Teo, E.L.,.. Dymock, B.W., Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptaco sa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. Journal of Medicinal Chemistry 55 (2012), 169–196.
263. Wilson, S.C., Atrash, B., Barlow, C., Eccles, S., Fischer, P.M., Hayes, A.,.. McDonald, E., Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. Bioorganic & Medicinal Chemistry 19 (2011), 6949–6965.
264. Wong, P., Iwasaki, M., Somervaille, T.C., So, C.W., Cleary, M.L., Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes & Development 21 (2007), 2762–2774.
265. Wyatt, P.G., Woodhead, A.J., Berdini, V., Boulstridge, J.A., Carr, M.G., Cross, D.M.,.. Woolford, A.J., Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. Journal of Medicinal Chemistry 51 (2008), 4986–4999.
266. Yadav, V., Burke, T.F., Huber, L., Van Horn, R.D., Zhang, Y., Buchanan, S.G.,.. Peng, S.B., The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Molecular Cancer Therapeutics 13 (2014), 2253–2263.
267. Yanagi, T., Matsuzawa, S., PCTAIRE1/PCTK1/CDK16: A new oncotarget?. Cell Cycle 14 (2015), 463–464.
268. Yang, J., Zhao, Y., Kalita, M., Li, X., Jamaluddin, M., Tian, B.,.. Brasier, A.R., Systematic Determination of Human Cyclin Dependent Kinase (CDK)-9 Interactome Identifies Novel Functions in RNA Splicing Mediated by the DEAD Box (DDX)-5/17 RNA Helicases. Molecular & Cellular Proteomics 14 (2015), 2701–2721.
269. Yang, L., Zhu, J., Huang, H., Yang, Q., Cai, J., Wang, Q.,.. Wang, Y., PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion. PLoS One, 10, 2015, e0140451.
270. Ye, X., Zhu, C., Harper, J.W., A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. Proceedings of the National Academy of Sciences of the United States of America 98 (2001), 1682–1686.
271. Yeo, W., Goh, B., Le Tourneau, C., Greenser, S.R., Siu, L.L., A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. Journal of Clinical Oncology, 27, 2009 (abstr 6026).
272. Yin, J.W., Wang, G., The Mediator complex: A master coordinator of transcription and cell lineage development. Development 141 (2014), 977–987.
273. Yokoyama, H., Gruss, O.J., Rybina, S., Caudron, M., Schelder, M., Wilm, M.,.. Karsenti, E., Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate. The Journal of Cell Biology 180 (2008), 867–875.
274. Zarkowska, T., Mittnacht, S., Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases. The Journal of Biological Chemistry 272 (1997), 12738–12746.
275. Zhang, H.S., Dean, D.C., Rb-mediated chromatin structure regulation and transcriptional repression. Oncogene 20 (2001), 3134–3138.
276. Zhang, T., Kwiatkowski, N., Olson, C.M., Dixon-Clarke, S.E., Abraham, B.J., Greifenberg, A.K.,.. Gray, N.S., Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology 12 (2016), 876–884.
277. Zhang, Y.X., Sicinska, E., Czaplinski, J.T., Remillard, S.P., Moss, S., Wang, Y.,.. Wagner, A.J., Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Molecular Cancer Therapeutics 13 (2014), 2184–2193.
278. Zhao, X., Feng, D., Wang, Q., Abdulla, A., Xie, X.J., Zhou, J.,.. Yang, F., Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. The Journal of Clinical Investigation 122 (2012), 2417–2427.
279. Zhao, J., Ramos, R., Demma, M., CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation. Oncogene 32 (2013), 3520–3530.
280. Zhou, Y., Han, C., Li, D., Yu, Z., Li, F., Li, F.,.. Kan, Q., Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth. Scientific Reports, 5, 2015, 10433.
281. Zhou, Y., Shen, J.K., Hornicek, F.J., Kan, Q., Duan, Z., The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. Oncotarget 7 (2016), 40846–40859.